Introduction {#Sec1}
============

The impact of gender on cardiovascular disease is well established and it would nowadays be inconceivable to carry out epidemiological studies on pathogenic factors or clinical intervention trials without separate analysis of female and male subjects. Unfortunately, identification of gender differences at the metabolic, endocrine, and cellular level has not yet translated into the anticipated clinical benefits, as shown by the failure of late-onset estrogen replacement to protect postmenopausal women against cardiovascular disease \[[@CR1]--[@CR3]\]. Yet, in addition to differences in pathogenetic mechanisms and responses to drugs there is a third, far less recognized area in which a greater focus on females promises substantial benefits.

Extensive epidemiological evidence supports the concept that the in utero environment influences the susceptibility to many diseases later in life. Barker and colleagues first noticed an association between low birthweight and adult cardiovascular disease, hypertension, and diabetes \[[@CR4]--[@CR6]\]. Later studies refined this by showing that adult cardiovascular risk was associated not with low birthweight per se, which may also reflect premature birth, but with impaired intrauterine growth \[[@CR7]\]. However, growth retardation is an outcome parameter of fetal development which may result from many pathogenetically diverse causes, ranging from extreme maternal undernutrition to mechanical obstruction of the uterine artery. In addition, fetal growth, especially in experimental models, may also vary considerably due to sibling competition. It is therefore increasingly recognized that elucidation of developmental programming should focus on maternal pathogenic factors, rather than outcome parameters \[[@CR8]\]. Furthermore, maternal conditions associated with overnutrition, such as hypercholesterolemia, obesity, hypertension, insulin resistance, and type 2 diabetes are far more prevalent in the developed world than severe undernutrition \[[@CR9]\]. The increasing prevalence of maternal obesity, gestational diabetes, and other dysmetabolic conditions, their association with offspring obesity and diabetic conditions, and the mounting evidence for atherogenic programming by specific maternal factors in experimental models suggest that pathogenic in utero programming may contribute to the expected wave of cardiovascular disease in their offspring \[[@CR9]--[@CR18]\].

On the other hand, results in experimental models suggest that pathogenic in utero programming may be prevented by relatively simple and safe interventions, as well as by treatment of the underlying maternal condition. In addition, preventive measures are likely to yield lifelong benefits for offspring. The following will provide a brief overview of developmental programming from a translational perspective (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Fetal programming of cardiovascular disease. Modified from reference \[[@CR87]\]

Programming by Maternal Undernutrition {#Sec2}
======================================

The fact that so many different factors may lead to impaired fetal growth in humans is a major obstacle in the search for the programming mechanisms, in particular when data from different continents with obvious genetic and dietary differences are compared. One way to reduce confounders is to focus on relatively homogeneous populations with a clearly defined and temporally limited cause of growth retardation, such as maternal starvation for children born during the Dutch Hunger Winter (1944--1945) \[[@CR19]\]. Although still ongoing, studies of this population have already shown a greater prevalence of obesity and, in some subgroups, an increased insulin resistance. Animal models of extreme undernutrition have established that exposure to excessive maternal glucocorticoids (or exogenously administered dexamethasone) during late pregnancy plays an important role in fetal growth retardation, as well as in adult insulin hyperglycemia, hyperinsulinemia \[[@CR20], [@CR21]\], hypertension \[[@CR22], [@CR23]\], and atherogenesis \[[@CR24]\]. Maternal protein restriction also induced offspring hypertension in rats \[[@CR25], [@CR26]\].

However, other studies in prematurely born human infants have indicated that increased, rather than reduced, growth during a critical postnatal period promotes insulin resistance \[[@CR27]\]. This points to a major practical problem. In contrast to conventional early predictors of adult cardiovascular risk, such as childhood endothelial dysfunction, atherogenesis, obesity, and insulin resistance, the pathogenic effects of fetal growth retardation cannot be corrected by compensatory weight gain after birth. Indeed, accelerated growth during childhood only increases later insulin resistance and hypertension, particularly in prematurely born children \[[@CR28]\].

Studies of fetal undernutrition have also prompted the hypothesis that fetal programming represents an attempt of the fetus to adapt to adverse conditions encountered in utero. If similar conditions, i.e. undernutrition, prevail later in life, such adaptation would be beneficial, whereas it would be detrimental in case of normal or abundant nutrition \[[@CR29]\]. If this hypothesis is correct, a therapeutical corollary would be that low-caloric diets should prevent cardiovascular disease in subjects born underweight for their gestational age. This corollary is at least consistent with the observation that postnatal overnutrition is particularly pathogenic in these subjects. The opposite corollary, i.e., that programming by gestational hypercholesterolemia, insulin resistance, or diabetes should be least pathogenic under continued postnatal exposure to conventional risk factors of these conditions seems distinctly less attractive.

Thus, although the correlation between fetal growth retardation and adult disease is supported by the majority of epidemiological studies and some animal studies, it is unlikely that pathogenic programming associated with impaired fetal growth will be preventable, unless growth retardation itself is prevented. In contrast, other fields of developmental programming have made significant progress towards this goal, as outlined below.

Programming by Maternal Hypercholesterolemia, Obesity, and Diabetic Conditions {#Sec3}
==============================================================================

Although clinical manifestations of atherosclerosis typically occur in adults, atherosclerotic lesions are found in most children \[[@CR30]--[@CR32]\] and prodromal lesions, fatty streaks, may already be formed during fetal development. The first indication that in utero exposure to cholesterol may program adult cardiovascular disease came from the observation that maternal hypercholesterolemia, even if temporary and limited to pregnancy only, is associated with a marked increase in fatty streaks in the aorta of premature human fetuses \[[@CR16]\]. The same study also showed that fetal cholesterol levels at the end of the second trimester are very high, even in fetuses of normocholesterolemic mothers, and decline linearly until term birth. This is consistent with the well-documented fact that in the absence of inherited genetic defects of lipid metabolism, such as familial hypercholesterolemia, cholesterol levels of term-born children are very low, even if their mothers are extensively hypercholesterolemic. It was therefore conceivable that fetal lesions would regress towards full term. Instead, the Fate of Early Lesions in Children (FELIC) study, a morphometric assessment of aortic atherosclerosis in normocholesterolemic children who died before the age of 14, demonstrated that maternal hypercholesterolemia is associated with greater atherogenesis throughout childhood \[[@CR17]\]. This observation could not be explained by conventional risk factors in mothers or children and suggested programming by maternal hypercholesterolemia or the ensuing increase in oxidative stress. A retrospective study correlating maternal cholesterol levels with the severity of myocardial infarction in young adults is currently under way to establish the effect of fetal programming on clinical manifestations of atherosclerosis.

In the human subjects of the FELIC study, genetic traits inherited from hypercholesterolemic mothers are likely to have contributed to increased atherosclerosis in their offspring. Direct experimental evidence for the causal role of maternal hypercholesterolemia was obtained in genetically more uniform models. For example, temporary, diet-induced maternal hypercholesterolemia prior to and during pregnancy led to dose-dependent increases in fetal lesion formation \[[@CR33]\] and postnatal atherogenesis in NZW rabbits \[[@CR34]\]. Conversely, maternal cholesterol-lowering with cholestyramine, considered safe during pregnancy, or with a natural antioxidant, vitamin E, greatly reduced offspring atherosclerosis \[[@CR33], [@CR34]\]. Similarly, maternal treatment with a statin during pregnancy (contraindicated in humans) reduced atherogenic programming in mice \[[@CR35]\]. The protective effect of antioxidants and cholesterol-lowering drugs also indicated an important role of oxidative stress in developmental programming, which is discussed in the following chapter.

Mouse and rat models also provided valuable insights into fetal programming. For example, moderate maternal hypercholesterolemia led to persistent changes in gene expression in the arterial intima and media prior to histologically detectable atherogenesis \[[@CR36]\]. It also enhanced offspring atherosclerosis in apoE-deficient (ApoE^−/−^) mice \[[@CR37]\], although others had failed to see an effect in this strain \[[@CR38]\]. One of the most important results was obtained by a comparison of heterozygous offspring generated by crossing wild-type apoE^+/+^ females with apoE^−/−^ males, and vice versa. Thus, all offspring were genetically identical, but exposed to either normal or mildly hypercholesterolemic conditions in utero, depending on their mothers \[[@CR39]\]. The degree of hypercholesterolemia achievable in apoE^+/−^ offspring was insufficient to induce significant atherosclerosis, but pathogenic programming manifested itself in the form of dramatically increased carotid atherosclerosis, once an additional atherogenic stimulus was added, in this case a non-constricting carotid cuff \[[@CR39]\]. These results highlight the fact that fetal programming effects may be latent and become apparent only in the presence of additional or more severe conventional risk factors, or, as shown recently in a model of spontaneous stroke, a combination of inherited genetic susceptibility and dietary factors acting synergistically \[[@CR40], [@CR41]\].

Wild-type rat models do not usually develop sufficiently high plasma cholesterol levels to cause atherosclerosis, but have indicated other mechanisms by which maternal high-fat, high-cholesterol diets during pregnancy may promote cardiovascular disease, such as impaired vascular reactivity in offspring \[[@CR42]--[@CR45]\]. Some of these effects were enhanced by maternal diabetes \[[@CR42]\], and conversely, high-fat diets promoted insulin resistance in offspring \[[@CR46]\]. Maternal exposure of rats to a high carbohydrate diet resulted in similar programming of hyperinsulinemia, which could be reduced by low-carbohydrate diets \[[@CR47]\].

Murine models of obesity and gestational diabetes have identified programming of factors involved in insulin signaling and insulin resistance itself \[[@CR48]\]. However, caution is indicated when extrapolating the effects of high-fat diets and obesity in mice to humans, because the C57\\BL6 strains appears to be genetically predisposed to type 2 diabetes \[[@CR49], [@CR50]\]. Furthermore, in many rodent models a clear distinction between pathogenic factors is impossible, because standard high-fat, high-cholesterol diets induce not just hypercholesterolemia but also obesity and insulin resistance \[[@CR51]\]. Such a distinction is less important for translational purposes, though, because obesity, insulin resistance and combined hyperlipidemia are prevalent in many human mothers, and synergism of pathogenic mechanism programmed in utero is likely.

Putative Mechanisms of Early-life Programming {#Sec4}
=============================================

Hypercholesterolemia is associated with enhanced lipid peroxidation and a wide range of oxidized fatty acids and other markers of lipid peroxidation are increased in fetal plasma and aortic lesions \[[@CR16], [@CR52]--[@CR54]\]. The first indication that increased oxidative stress might play a role in atherogenic programming was provided by a study in premature human fetuses which showed that intracranial arteries, which had higher activities of antioxidant enzymes, developed less atherosclerosis in response to maternal hypercholesterolemia than extracranial arteries \[[@CR52]\]. A similar observation later linked an acceleration of intracranial atherogenesis in elderly human subject to an age-related decrease in antioxidative protection \[[@CR55]\]. Given that OxLDL enhances adult atherogenesis by a number of mechanisms, including interference with many oxidation-sensitive nuclear signaling pathways \[[@CR56]\], we proposed that oxidative stress is important in developmental programming by maternal hypercholesterolemia \[[@CR17], [@CR57]\]. This notion was supported by the prevention of atherogenic programming achieved by maternal treatments which reduced lipid peroxidation either directly (antioxidants) or by reducing plasma cholesterol (cholestyramine, statins) \[[@CR33], [@CR34]\]. Later studies also established an involvement of oxidative stress in the fetal programming of vascular dysfunction and hypertension \[[@CR58]\].

Lipid peroxidation products (reactive aldehydes, ketones, and oxidized phospholipids) modify biological properties of many proteins by forming adducts with free amino groups. They may also affect DNA. In fact, much attention has focused on DNA methylation and other epigenetic effects \[[@CR59]\]. In utero conditions indeed result in specific epigenetic changes \[[@CR60], [@CR61]\]. However, there is no evidence that epigenetic changes actually cause or contribute to increased disease manifestation in offspring. Another possibly related mechanism is the alteration of mitochondrial DNA \[[@CR46]\]. This is intuitively attractive, because mitochondrial DNA is inherited exclusively from the mother and would therefore allow the transfer of fetal programming "memory" to successive generations.

Finally, we have recently shown in both rabbit and murine models that immune mechanisms may influence fetal programming. Maternal immunization with homologous OxLDL prior to hypercholesterolemic pregnancy effectively reduced atherogenic programming in their offspring, probably by reducing fetal exposure to circulating mildly oxidized LDL \[[@CR18]\]. In fact, increased formation of antibodies to oxidation-specific epitopes had previously been shown to reduce atherogenesis in adult animals, in part by formation and rapid elimination of immune complexes \[[@CR62]\]. Unexpectedly, the beneficial effect was not limited to offspring of hypercholesterolemic mothers. Furthermore, titers of protective IgM antibodies and IgM-LDL immune complexes were persistently increased in adult offspring of immunized mothers. Naïve adult offspring never exposed to increased oxidative stress also showed markedly increased B cell-dependent IgM and IgG responses to antigenic challenge with selective oxidation-specific epitopes. These results demonstrate that immature fetal lymphocytes are programmed in utero. Previously, it was presumed that maternal adaptive immunity protects the neonate mainly by transplacental passage of maternal IgG, and in utero programming of B and T cells had only be shown in connection with increased IgE responses to allergens. Our findings showed that it is possible to modulate in utero programming of beneficial IgM and IgG responses by maternal immunization prior to pregnancy.

Elucidation of fetal immune programming is still in its infancy, but the above data also emphasize the importance of inflammation in in utero programming. Whether its role will be as complex as in atherosclerosis remains to be seen \[[@CR63]\]. All of the maternal conditions of overnutrition discussed above promote inflammation. Furthermore, markers of inflammation, such as CRP, correlate with the extent of fetal atherogenesis in humans \[[@CR64]\]. Similarly, increased CRP was observed in infants of mothers with type 1 diabetes \[[@CR65]\]. Thus, proinflammatory cytokines will have to be considered as potential causes of programming, and makers of inflammation as potential predictors.

A good example that fetal programming by the same maternal factor may involve not just one but many of the mechanisms described above is provided by maternal smoking. This has been shown to increase formation of reactive oxygen species or reduce antioxidant activities \[[@CR66], [@CR67]\], to affect immune mechanisms \[[@CR68]\], to impair the development of the lung and heart \[[@CR69], [@CR70]\], to affect mitochondrial DNA \[[@CR67]\], and to enhance hypertension \[[@CR71]\] in human and animal offspring.

The Role of the Placenta {#Sec5}
========================

The atherogenic programming effect of maternal hypercholesterolemia and the observation of strikingly high fetal cholesterol levels at the end of second trimester \[[@CR16]\] raised new interest in maternal--fetal cholesterol transport. Could it be that maternal cholesterol crosses the placental barrier, which is impenetrable for lipoprotein particles? This possibility had already been postulated because of the survival of human fetuses with the Smith Lemli Opitz syndrome, which cannot synthesize cholesterol and therefore depend on maternal cholesterol \[[@CR72]\]. Evidence for maternal--fetal cholesterol transport had also been provided by the identification of active transport mechanisms on the maternal side of the placenta in rabbits \[[@CR73]\] and hamsters \[[@CR74]\]. The last step in transplacental cholesterol transport mechanism---the export from endothelial cells lining the placental villi into the lumen of fetal microvessels---has recently been elucidated \[[@CR75]\]. Results indicate that regulation of these mechanisms by increased fetal demand for cholesterol differs from that induced by maternal hypercholesterolemia \[[@CR76]\]. Increased cholesterol transport, at least during parts of gestation, may therefore constitute one mechanism by which maternal hypercholesterolemia affects fetal programming.

In addition to maternal factors crossing the placental barrier, it is important to remember that the placenta is not a passive filter between mother and fetus, but that it can be both target and source of pathogenic factors affecting the fetus. A recent comparison of the activities of antioxidant enzymes in human maternal and fetal plasma and placental tissue from normo- and hypercholesterolemic subjects has shown that the placenta can both protect against, and contribute to, fetal oxidative stress \[[@CR77]\]. Unfortunately, the placenta of many lower animal models shows significant anatomical and functional differences, compared to the human placenta, which complicates the investigation of its role in developmental programming.

Programming of Hypertension {#Sec6}
===========================

Hypertension is a major risk factor of cardiovascular disease that is influenced by early-life programming, and hypertension during pregnancy is a leading cause of maternal and perinatal mortality. However, there is little evidence that maternal hypertension directly affects fetal programming. In fact, most insights into in utero modulation of hypertensive mechanisms were obtained in models of maternal hypercholesterolemia or obesity \[[@CR42], [@CR44], [@CR78], [@CR79]\] or impaired fetal growth \[[@CR22], [@CR80], [@CR81]\]. Nevertheless, fetal exposure to high salt concentrations promotes offspring hypertension in both salt-sensitive and salt-resistant rat strains \[[@CR82], [@CR83]\]. A more complex causality was recently established in a novel rat model combining genetic salt susceptibility, expression of human cholesterol ester transfer protein, and mild dietary salt exposure \[[@CR40]\]. Salt exposure began during pregnancy, at weaning, or early adult age. Both fetal and at weaning onset of salt exposure resulted in extensive spontaneous stroke. Thus, the critical period was not limited to fetal development, but included lactation and infancy \[[@CR40], [@CR41]\].

A Word of Caution {#Sec7}
=================

Throughout this review, the authors have taken some liberty with the terms referring to developmental programming. This reflects the present lack of understanding not only of the mechanisms involved, but also of the timeframe. Fetal (i.e., in utero) programming and programming during lactation probably constitute a single entity. Childhood conditions also markedly influence adult disease manifestation and may enhance or attenuate the effects of fetal programming. Again, the mechanisms are largely unknown, but conditioning during childhood clearly represents a different entity than fetal programming. Finally, we should be aware that early-life exposure to pathogenic factors may predispose one to adult disease manifestation by at least three very different mechanisms. First, by actual programming events resulting in permanent differences in gene expression or epigenetic changes. Second, by impaired development of tissues or organs, which may persist over time in the form of altered cellular composition or reduced functionality. The latter is probably true for the lungs of asthmatic children whose mothers smoked during pregnancy. Third, neonates/infants may just be particularly vulnerable to specific injury, e.g. by toxins or free radicals. In this case, the same insult would cause lesser damage in adults, but the mechanisms would not be different, and no programming would be involved. From a translational perspective, this distinction should not be very relevant, as long as we can find ways to prevent the pathogenic events in the fetus from occurring.

Conclusion {#Sec8}
==========

Increasing evidence indicates that maternal hypercholesterolemia, obesity, and diabetic conditions during pregnancy influence fetal development and predispose offspring to cardiovascular disease. Animal models have established cause--effect relationships for some maternal factors and led to the identification of specific epigenetic changes, but the nature of fetal programming and the mechanisms by which they actually promote adult disease remain largely unknown. Similarly, most of the maternal factors responsible for fetal programming remain unknown. The National Children\'s Study, a prospective study designed to document maternal pathologies and exposure to environmental risk factors and to follow 100,000 of their children to the age of 25 years, will probably identify many more of these factors and establish better correlations with offspring effects \[[@CR84]--[@CR86]\]. Sadly, this will come rather late for the children of the increasing number of current high-risk mothers. A greater-than-usual emphasis on experimental models and on translational studies is indicated in order to explore the mechanisms and to identify potential targets for intervention \[[@CR87]\].

Supported by National Institutes of Health grant HL-089559 (W.P.), Progetto di Rilevanza Nazionale from the Italian Ministery of University and Research PRIN 2006 (C.N.) and an Ellison Medical Foundation Senior Scholar Award (W.P.).

**Conflicts of Interest** E. Nicolaides is Managing Partner of a venture capital enterprise interested in prevention of developmental programming. W. Palinski is a co-inventor of several UCSD patents on immunomodulation.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
